Connolly H M, Nishimura R A, Smith H C, Pellikka P A, Mullany C J, Kvols L K
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905.
J Am Coll Cardiol. 1995 Feb;25(2):410-6. doi: 10.1016/0735-1097(94)00374-y.
The hypothesis was that cardiac surgery for symptomatic carcinoid heart disease in conjunction with adjunctive therapy could improve the long-term outlook of patients with carcinoid heart disease.
Patients with carcinoid heart disease have a dismal prognosis; most die of progressive right heart failure within 1 year after onset of symptoms. Improved therapies for the systemic manifestations of the carcinoid syndrome have resulted in symptomatic improvement and prolonged survival in patients without heart disease.
Twenty-six patients with symptomatic carcinoid heart disease underwent valvular surgery. Preoperative clinical, laboratory, Doppler echocardiographic and hemodynamic factors were evaluated. The survival of the surgical group was compared with that of a control group of 40 medically treated patients.
There were nine perioperative deaths (35%), primarily from postoperative bleeding and right ventricular failure. Of the 17 surgical survivors, 8 were alive at a mean of 28 months of follow-up. The postoperative functional class of the eight surviving patients was substantially improved. Late deaths were primarily due to hepatic dysfunction caused by metastatic disease. The only predictor of operative mortality (p = 0.03) was low voltage on preoperative electrocardiography (limb lead voltage < or = 5 mm). Predictors of late survival included a lower preoperative somatostatin requirement and a lower preoperative urinary 5-hydroxy-indoleacetic acid level. There was a trend toward increased survival for the surgical group compared with the control group.
Because new therapies have improved survival in patients with the malignant carcinoid syndrome, cardiac involvement has become a major cause of morbidity and mortality. Valve surgery is the only definitive treatment. Although cardiac surgery carries a high perioperative mortality, marked symptomatic improvement occurs in survivors. Surgical intervention should therefore be considered when cardiac symptoms become severe.
本研究的假设是,针对有症状的类癌性心脏病进行心脏手术并辅以辅助治疗,可改善类癌性心脏病患者的长期预后。
类癌性心脏病患者预后不佳;大多数患者在症状出现后1年内死于进行性右心衰竭。针对类癌综合征全身表现的改良疗法已使无心脏病患者的症状得到改善,生存期延长。
26例有症状的类癌性心脏病患者接受了瓣膜手术。对术前临床、实验室、多普勒超声心动图和血流动力学因素进行了评估。将手术组的生存率与40例接受药物治疗的对照组患者的生存率进行了比较。
围手术期死亡9例(35%),主要死于术后出血和右心室衰竭。17例手术幸存者中,8例在平均28个月的随访期内存活。8例存活患者术后功能分级有显著改善。晚期死亡主要归因于转移性疾病导致的肝功能障碍。手术死亡率的唯一预测因素(p = 0.03)是术前心电图低电压(肢体导联电压≤5 mm)。晚期生存的预测因素包括术前生长抑素需求量较低和术前尿5-羟吲哚乙酸水平较低。与对照组相比,手术组有生存率增加的趋势。
由于新疗法提高了恶性类癌综合征患者的生存率,心脏受累已成为发病和死亡的主要原因。瓣膜手术是唯一的确定性治疗方法。尽管心脏手术围手术期死亡率较高,但幸存者症状有显著改善。因此,当心脏症状严重时应考虑手术干预。